Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GM3 (Neu5Gc) ganglioside is a glycosphingolipid found on the surface of cells, particularly enriched in certain cancers. It consists of a ceramide lipid anchor, a lactosylceramide core, and one N-glycolylneuraminic acid (Neu5Gc) residue. Humans lack the enzyme to synthesize Neu5Gc, making it a tumor-associated antigen and a target for cancer immunotherapy.
Targeting with monoclonal antibodies or CAR-T cells to induce cell death in tumor cells expressing GM3(Neu5Gc).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GM3 (Neu5Gc) ganglioside.